No Data
No Data
ST Tiansheng (002872.SZ) announced first-quarter results with a net loss of 20.46 million yuan
ST Tiansheng (002872.SZ) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved revenue of 148 million yuan, a year-on-year decrease of 5.98%; a net profit loss of 20.46 million yuan to mother; and a loss of 22.36 million yuan in non-net profit. Basic earnings per share - $0.0643.
ST Tiansheng (002872.SZ): Expected net loss of 75 million yuan to 105 million yuan in 2023
Gelonghui, January 30 | ST Tiansheng (002872.SZ) announced that it is expected to have a net loss of 75.0 million yuan to 10,500,000 yuan in 2023, after deducting non-net loss of 95.0 million yuan to 130.0 million yuan, and operating income of 520.00 million yuan to 615.00 million yuan. The main reason for the loss in the company's performance during the reporting period was insufficient capacity utilization of the new production line and high fixed costs such as depreciation of fixed assets and labor costs.
The controlling shareholder of ST Tiansheng (002872.SZ) has released all of its pledged shares
ST Tiansheng (002872.SZ) issued an announcement. The company recently inquired about China Securities Registration and Settlement Co., Ltd...
ST Tiansheng (002872.SZ): Currently, some products have been transferred to the new workshop for production, and other varieties are still being transferred
Gelonghui November 17丨ST Tiansheng (002872.SZ) held a performance briefing on November 17, 2023, on “When will all of the new smart factories be relocated?” The company replied that with the gradual commissioning of smart factories, at present, some products have been transferred to new workshops for production, while other varieties are still being transferred.
ST Tiansheng (002872.SZ): Acetaminophen tablets passed generic drug consistency evaluation
ST Tiansheng (002872.SZ) issued an announcement. The company recently received approval from the State Drug Administration...
ST Tiansheng (002872.SZ) obtained the sodium acetate Ringer injection registration certificate
Zhitong Finance App News, ST Tiansheng (002872.SZ) announced that the company obtained the “Drug Registration Certificate” for sodium acetate Ringer injection approved and issued by the State Drug Administration. It falls into category 3 chemicals, and is considered to have passed a consistent evaluation of the quality and efficacy of generic drugs. Clinically, sodium acetate Ringer injection is mainly used to supplement extracellular fluid when circulating blood volume and intertissue fluid decrease, and to correct metabolic acidosis.
No Data